Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (NASDAQ:DRNA) (up 160%) or Ultragenyx (NASDAQ:RARE) (110%), last week’s biotechs averaged only a 5% return. Non-biotechs included, last week’s offerings had the smallest deal sizes and market caps on average so far this year ($76 million and $313 million respectively). While Sundance Energy (Pending:SNDE) is the only IPO on the calendar for this week, an unusually high number of initial filings introduced some highly anticipated PE-backed companies and indicated that technology could be the next hot IPO sector.
Six health care IPOs and overall weak returns
The week’s total returns averaged 2% and brought total YTD IPO gains down to 20% from 25%. As we reported Thursday, IBP continued a pattern of housing companies trading up after slashing their offering prices. WL Ross-backed Talmer Bancorp was the third financial IPO of the year after Ladder (NYSE:LADR) and Santander (NYSE:SC), and it edged the previous two with a mediocre 7% return. Amedica (NASDAQ:AMDA), a medical device company that creates enhanced spine, hip and knee replacements using silicon nitride, had the largest discount of the year (priced 48% below the midpoint), and has fallen another 1%. A maker of battery-powered portable oxygen concentrators, Inogen priced 6% below its midpoint and then dropped 5% on its first day of trading. And despite billing itself as a deuterium-enhancement biotech like Auspex (NASDAQ:ASPX) (up 99%), Concert’s (NASDAQ:CNCE) debut fell on deaf ears; the stock has traded up only 1%. Investors may have had their fill of biotechs, though Flexion Therapeutics (NASDAQ:FLXN), which makes sustained-release pain treatments, performed at the front of the biotech pack with a decent 16% total return.
|IPO pricings (week of February 10, 2014)|
|Company (Ticker)||Business||Deal Size ($mm)||IPO Price vs. Midpoint||Return as of 2/14|
|Installed Building Products (NYSE:IBP)||US residential insulation installer||$82||-27%||18%|
|Flexion Therapeutics (FLXN)||Slow-release osteoarthritis pain therapy||$65||0%||16%|
|Talmer Bancorp (NASDAQ:TLMR)||WL Ross-backed Midwest regional bank||$202||-4%||7%|
|Concert Pharmaceuticals (CNCE)||Deuterium enhanced drugs||$84||8%||1%|
|NephroGenex (NASDAQ:NRX)||Treatments for diabetic nephropathy||$37||-8%||-1%|
|Amedica (AMDA)||Enhanced spine, hip and knee replacements||$20||-48%||-1%|
|Inogen (NASDAQ:INGN)||Portable oxygen concentrators||$71||-6%||-5%|
|Eagle Pharmaceuticals (NASDAQ:EGRX)||Enhanced injectable versions of drugs||$50||0%||-15%|
Two small health care companies launch
Last week continued a downward trend of launches on the calendar, down to just 2 from 11, 6 and 4 during the previous three weeks. Lumenis (NASDAQ:LMNS) is expected to price the week of February 24 and sells laser-based medical systems used in surgical, ophthalmic and aesthetic procedures. It is scheduled to be the first Israel-based US IPO since November, and the first in a string of four Israeli health care companies that were added to the pipeline this year. Recro Pharma (NASDAQ:REPH), which has not disclosed a pricing date, trails an unusually high number of pain-focused biotechs this year, which have averaged 9% gains.
|IPOs setting terms (week of February 10, 2014)|
|Company (Ticker)||Business||Deal Size ($mm)||LTM Sales ($mm)|
|Lumenis (LMNS)||Laser-based systems used in medical procedures||$100||$265|
|Recro Pharma (REPH)||Non-opioid therapeutics for pain treatment||$28||$0|
Several SaaS filers and two large PE-backed firms
As biotech activity slows, technology IPOs look poised to race ahead. Last week's five technology filers, all of them SaaS-related, raised the number of technology firms in the pipeline that have filed in the past 90 days from 9 to 14. Health care companies are still ahead with 16 in the 90-day pipeline, and together the two sectors represent 60% of filers. By far the largest deal added last week was PQ Holdings (Pending:PQH), which expects to raise $450 million. The silica-based inorganic chemical producer was bought in 2007 for $1.5 billion by the Carlyle Group, which reduced its stake to 60% after PQ's merger with INEOS Silicas in 2008. La Quinta (LAQ.RC), a budget hotel chain that we expect to raise up to $250 million, is the other new PE-backed filer. Blackstone bought the company in 2006 for $3.4 billion, and its IPO would represent the third major Blackstone-backed hotel IPO recently, after those of Extended Stay (NYSE:STAY) in November and Hilton (NYSE:HLT) in December. Both Extended Stay and Hilton will disclose year-end financial results next week, which could impact the timing of La Quinta's debut.
|New IPO filers (week of February 10, 2014)|
|Company (Ticker)||Business||Deal Size ($mm)||LTM Sales ($mm)|
|PQ Holdings (PQH)||Carlyle-backed producer of silica-based chemicals||$450||$1,089|
|21st Century Oncology Holdings (CONC.RC)||Largest integrated cancer treatment network||$300||$702|
|La Quinta Inns & Suites (LAQ.RC)||Blackstone-backed US budget hotel operator||$250*||$861|
|Q2 Holdings (NYSE:QTWO)||Cloud-based virtual banking for regional institutions||$138||$53|
|Stalwart Tankers (Pending:STST)||Acquire and operate mid-size chemical tankers||$100||$24|
|Castlight Health (NYSE:CSLT)||Software used to compare health care costs||$100||$13|
|MediWound (NASDAQ:MDWD)||Treatments for severe burns and chronic wounds||$86||$0|
|Aerohive Networks (NYSE:HIVE)||Cloud-enabled Wi-Fi and routing products||$75||$98|
|Amber Road (NYSE:AMBR)||Cloud-based global trade management software||$75||$53|
|Akebia Therapeutics (NASDAQ:AKBA)||Treatments for anemia and kidney disease||$75||$0|
|Rimini Street (Pending:RMNI)||Independent enterprise software support||$60||$55|
IPO market snapshot
So far this year, the Renaissance IPO ETF, a basket of newly public companies that trades under the symbol IPO, has gained 4%. The 35 IPOs in 2014 have raised $6.8 billion and produced an average return of 20% from the IPO price. There have been 54 IPOs in the past 90 days, with total proceeds of $13.1 billion and an average return of 34% from the IPO price, and a post-IPO return of 11%, as measured by the Renaissance IPO ETF. The active IPO pipeline includes 98 companies looking to raise a total of $25.4 billion.